Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Burning Rock BiotechBNR -10.19%57 3-Year EBITDA Growth Rate is 66.90% as of Mar. 2026. GuruFocus rates BNR with a GF Score™ of 57/100 and a GF Value™ of $7.45 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 166 Medical Diagnostics & Research companies, Burning Rock Biotech ranks better than 94.58% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 66.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 41.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Burning Rock Biotech was 66.90% per year. The lowest was -77.50% per year. And the median was -1.75% per year.
Burning Rock Biotech (NAS:BNR) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Burning Rock Biotech 3-Year EBITDA Growth Rate Related Terms
BNR vs XGN, PRPO, IDXG: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's 3-Year EBITDA Growth Rate falls into.
Burning Rock Biotech 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 66.90% mean?
Burning Rock Biotech (BNR) has a 3-Year EBITDA Growth Rate of 66.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Burning Rock Biotech and its competitors. According to the industry distribution chart, Burning Rock Biotech ranks #9 out of 166 companies in the Medical Diagnostics & Research industry, placing it in the top 5.4%.
Is Burning Rock Biotech's 3-Year EBITDA Growth Rate too high?
Burning Rock Biotech's current 3-Year EBITDA Growth Rate is 66.90%. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 10.80. Burning Rock Biotech's value of 66.90% is 519.4% above this industry median. Based on the distribution chart, Burning Rock Biotech ranks #9 out of 166 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Burning Rock Biotech has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's 3-Year EBITDA Growth Rate compare to XGN and PRPO?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #9 out of 166 companies for 3-Year EBITDA Growth Rate. This places Burning Rock Biotech in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 10.80. Burning Rock Biotech's value of 66.90% is 519.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 10.80, based on 166 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Burning Rock Biotech's current 3-Year EBITDA Growth Rate of 66.90% is 519.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Burning Rock Biotech and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burning Rock Biotech's current 3-Year EBITDA Growth Rate is 66.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (BNR) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.45, compared to a current price of $9.78 — trading 31.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 66.90% and 519.4% above the Medical Diagnostics & Research industry median of 10.80. Burning Rock Biotech's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Burning Rock Biotech (BNR), the current 3-Year EBITDA Growth Rate is 66.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (BNR) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of $9.78 is trading 31.3% above its estimated GF Value™ of $7.45.
GuruFocus considers Burning Rock Biotech to be Significantly Overvalued.
Key valuation signals for BNR:
3-Year EBITDA Growth Rate: 66.90%
GF Value™: $7.45 vs. price of $9.78 (31.3% above fair value)
Industry Position: 519.4% above the Medical Diagnostics & Research median (#9 of 166)
No single metric tells the full story. See the BNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
57GF Score
Get the complete analysis for BNR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNR has been successfully added to your 
